Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1530/eje.1.02061
European Journal of Endocrinology, Vol 154, Issue 1, 69-74
Copyright © 2006 by European Society of Endocrinology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sigurjónsdóttir, H. A
Right arrow Articles by Johannsson, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sigurjónsdóttir, H. A
Right arrow Articles by Johannsson, G.

CLINICAL STUDY

GH effect on enzyme activity of 11ßHSD in abdominal obesity is dependent on treatment duration

Helga Á Sigurjónsdóttir, Josef Koranyi, Magnus Axelson1, Bengt-Åke Bengtsson and Gudmundur Johannsson

Research Centre for Endocrinology and Metabolism, Sahlgrenska University Hospital, 41345 Gothenburg, Sweden and 1 Department of Clinical Chemistry, Karolinska Hospital, Stockholm, Sweden

(Correspondence should be addressed to H Á Sigurjónsdóttir; Email: helga.sigurjonsdottir{at}medic.gu.se)

Objective: In the past years the interaction of GH and 11ßhydroxysteroid dehydrogenase (11ßHSD) in the pathogenesis of central obesity has been suggested.

Design: We studied the effects of 9 months of GH treatment on 11ßHSD activity and its relationship with body composition and insulin sensitivity in 30 men with abdominal obesity, aged 48–66 years, in a randomised, double-blind, placebo-controlled trial.

Methods: Urinary steroid profile was used to estimate 11ßHSD type 1 and 2 (11ßHSD1 and 11ßHSD2) activities. Abdominal s.c. and visceral adipose tissues were measured using computed tomography. Glucose disposal rate (GDR) obtained during a euglycaemic–hyperinsulinaemic glucose clamp was used to assess insulin sensitivity.

Results: In the GH-treated group the 11ßHSD1 activity decreased transiently after 6 weeks (P < 0.01) whereas 11ßHSD2 increased after 9 months of treatment (P < 0.05). Between 6 weeks and 9 months, GDR increased and visceral fat mass decreased. Changes in 11ßHSD1 correlated with changes in visceral fat mass between baseline and 6 weeks. There were no significant correlations between 11ßHSD1 and 11ßHSD 2 and changes in GDR.

Discussion: The study demonstrates that short- and long-term GH treatment has different effects on 11ßHSD1 and 11ßHSD2 activity. Moreover, the data do not support that long-term metabolic effects of GH are mediated through its action on 11ßHSD.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 European Society of Endocrinology.